Emend IV
(Fosaprepitant)PreclinicalSmall molecule
Merck & Co.Fosaprepitant is used to prevent nausea and vomiting caused by chemotherapy treatment for cancer. It works by blocking signals in the brain that trigger these side effects.[1] Emend IV is currently being investigated across 3 indications[3], with its most advanced program in Preclinical.[1]
Emend IV is one of 71 small molecule programs targeting Vomiting. It is currently in Preclinical.
3
Indications
25
Total Trials
4
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
254 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Balstilimab
AAgenus Inc.
Phase 3
5-Fu
TToray Industries, Inc
Phase 3
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Phase 3
Cytokine-Induced Killer Cells
TThe First People's Hospital of Changzhou
Phase 3
BL-M07D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
TQB2102
CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
Calcium Levofolinate
FFujian Cancer Hospital
Phase 3
Leucovorin and 5-FU
AAkeso
Phase 3
Trodelvy
GileadPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chemotherapy-induced nausea and vomiting3 trials
Nausea and vomiting3 trials
Dexamethasone2 trials
PrEP2 trials
14 more indications
Breast Cancer1 trial
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05841849·1,028 enrolled
Nasopharyngeal Carcinoma1 trial
Cervical Cancer1 trial
Thoracic Surgery1 trial
Carboplatin1 trial
Low Dose Aprepitant for Patients Receiving Carboplatin
Terminated·—·Phase 2·NCT03237611·15 enrolled
Advanced NSCLC1 trial
General Anesthesia1 trial
Prospective1 trial
Vomiting1 trial
Multiple Myeloma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fosaprepitant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Neurokinin 1 Receptor Antagonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company